The rising need for therapeutic antibodies, particularly monoclonal and polyclonal antibodies, is a major driver driving market expansion.
The global Antibody Therapeutics and Blood Antibody Therapeutics market is expected to develop $445 Billion by 2028, at a compound annual increase in price (CAGR) of 13.2% throughout the forecast period.
Covid-19 impact and market status
The covid-19 pandemic initially caused a major supply chain disruption for the healthcare and pharmaceutical industries. Furthermore, the pandemic has impacted the research, manufacture, and supply of medications and other healthcare items, as well as the expansion of many corporations' healthcare enterprises throughout the world. The market's major companies have likewise seen a decrease in their product sales growth. Humira, which was one of the top-selling drugs during the pandemic, witnessed positive growth over 2019. Few other antibody drugs such as Johnson & Johnson’s Remicade and Roches’ Herceptin saw a decline in the demand and revenues over 2019. The covid-19 pandemic has positively impacted the antibody therapeutics and blood antibody therapeutics market as many companies are aiming to launch antibody-based treatments for Covid-19 infected patients.
Monoclonal antibodies segment expected to dominate the global market
During the projected period, monoclonal antibodies are expected to dominate the global antibody therapeutics and blood antibody therapeutics markets. Monoclonal antibodies are proteins produced in a laboratory that help the immune system combat dangerous antigens or diseases. The monoclonal antibody market is estimated to hold the largest market in the coming few years.
The cancerous disease segment is forecasted to increase the growth of the market
Various forms of cancers have been rising in the recent few years owing to sedentary lifestyles post-pandemic, mutations, unhealthy eating habits, increased stress, and genetic reasons. This is one of the most important factors driving the market for antibody therapies and blood antibody therapeutics to rise. Autoimmune illnesses are also expected to fuel market expansion.
Medical and experimental segments are estimated to hold the largest market share
There has been a growth in research and development activities for different antibody manufacturing, resulting in market expansion. Antibodies are in high demand across the world, which is projected to fuel expansion in this market.
Asia-Pacific is expected to be the fastest-growing region for the market
As the healthcare infrastructure, increasing purchasing power lowered regulatory hurdles; better pharmaceutical investments are expected to propel the market growth.
Retail pharmacy segment to likely to grow during the forecast
The hospital pharmacy segment generated the maximum revenue because of more lenient guidelines, health reimbursement favoring policies, and government initiatives for chronic diseases. The retail pharmacy market is predicted to raise throughout the forecast period, owing to manufacturers' increased emphasis on extending distribution networks, a large increase in the number of cancer patients, and improved health infrastructure.
Effective harmonization of the development of the product, registration guidelines, and approval in the major market, such as the United States and the Asia Pacific region can speed up the growth and development of antibody therapeutics and bloody antibody therapeutics.
Antibodies are proteins generated in the body by blood plasma cells in response to certain antigens. Antibodies are used to diagnose and treat a variety of disorders, including rheumatoid arthritis, non-Hodgkin lymphoma, Crohn's disease, and others. Owing to R&D and several product launches, the antibody market is expected to grow steadily.
A key factor that is driving the market growth of the market is the patent expiry of various successful antibodies. Antibody treatments such as Mabthera, Herceptin, and Avastin will soon lose their patents. This will give an opportunity to other companies to come up with similar antibody treatments. The demand for the products is likely to increase as a result of this.
Another major driver of growth is the improvement in the production of therapeutic antibodies has led to a reduction in the cost of manufacturing. This has allowed the adoption of antibody therapeutics and blood antibody therapeutics market to expand in the cost-sensitive markets.
An increase in the investments in research & development activities across the globe by major biotechnology and pharmaceutical companies is expected to propel the global antibody therapeutics and blood antibody therapeutics market during the forecast period.
A major challenge of the market is that variations in antibody techniques lead to improper reproductive results. These variations affect the results of the research as well as the clinical screening tests. Antibody development is a time-consuming and difficult procedure. The need for huge bioreactors and filtering systems to generate antibodies is one of the primary challenges. The market's growth may be slowed as a result of this.
To maintain their positions in the highly competitive global antibody therapeutics and blood antibody therapeutics market, major firms employ a variety of growth tactics. Industry leaders in the global polyclonal antibody market use a variety of methods, including partnerships, mergers and acquisitions, cooperation, and research.
The key players of the Antibody Therapeutics and Blood Antibody Therapeutics market are Abbvie, Roche, Johnson & Johnson, Eli Lilly And Company, Novartis, Merck, Bristol-Myers Squibb, Alexion Pharmaceuticals, Amgen, Takeda, Biogen, Ucb, and AstraZeneca.
Recent innovations in the Antibody Therapeutics and blood antibody therapeutics market: a Snapshot
- The US Food and Drug Administration granted Regeneron Pharmaceuticals emergency use authorization for imdevimab and casirivimab for the treatment of Covid-19 in November 2020.
- ERELZI, a Novartis biosimilar of Enbrel, has been authorized in the United States. ERELZI was authorized by the European Union in April 2017. Novartis opened a large market opportunity in 28 European Union States with this authorization.
Antibody Therapeutics and Blood Antibody Therapeutics Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||$445 Billion|
|Growth Rate||CAGR of 13.2% during 2021-2028|
|Segment Covered||by Type, Antibody-Drug Conjugates, End-use, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, South America|
|Key Players Profiled||Merck & Co, Inc, Regeneron Pharmaceuticals Inc., Novartis AG, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline plc, Takeda Pharmaceuticals F. Hoffmann-La Roche Ltd., Seagen, AbbVie Inc, Amgen, Bristol Myers Squibb, Johnson & Johnson among others.|
Key Segments of the Antibody Therapeutics and the blood therapeutics market
Product type Overview, 2018-2028 (USD Billion)
- Monoclonal antibodies
- Polyclonal Antibodies
- Type I to Type VIII
- Antibody-drug complexes
- Immunogen Technology
- Seattle Genetic Technology
Indication Overview, 2018-2028 (USD Billion)
- Autoimmune diseases
- CNS disorders
- Infectious diseases
End-User Overview, 2018-2028 (USD Billion)
- Research Institute
- Diagnostics laboratories
Distribution Channels Overview, 2018-2028 (USD Billion)
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Application Overview, 2018-2028 (USD Billion)
- Western blot
- Radio immune Assays
Regional Overview, 2018-2028 (USD Billion)
- North America
- Rest of Europe
- Asia Pacific (APAC)
- Australia and New Zealand (ANZ)
- Rest of APAC
- Middle East and Africa (MEA)
- United Arab Emirates (UAE)
- South Africa
- Saudi Arabia
- Rest of MEA